Does ABALOPARATIDE Cause Injection site discolouration? 92 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 92 reports of Injection site discolouration have been filed in association with ABALOPARATIDE (Tymlos). This represents 0.4% of all adverse event reports for ABALOPARATIDE.
92
Reports of Injection site discolouration with ABALOPARATIDE
0.4%
of all ABALOPARATIDE reports
0
Deaths
3
Hospitalizations
How Dangerous Is Injection site discolouration From ABALOPARATIDE?
Of the 92 reports, 3 (3.3%) required hospitalization.
Is Injection site discolouration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ABALOPARATIDE. However, 92 reports have been filed with the FAERS database.
What Other Side Effects Does ABALOPARATIDE Cause?
Headache (4,048)
Nausea (3,134)
Dizziness (3,005)
Fatigue (2,637)
Heart rate increased (2,092)
Palpitations (1,730)
Arthralgia (1,711)
Bone pain (1,360)
Back pain (1,229)
Pain (1,191)
What Other Drugs Cause Injection site discolouration?
ETANERCEPT (1,846)
DUPILUMAB (779)
CERTOLIZUMAB PEGOL (597)
ADALIMUMAB (554)
EVOLOCUMAB (476)
GLATIRAMER (270)
EXENATIDE (266)
TERIPARATIDE (249)
ASFOTASE ALFA (243)
ENBREL (231)
Which ABALOPARATIDE Alternatives Have Lower Injection site discolouration Risk?
ABALOPARATIDE vs ABATACEPT
ABALOPARATIDE vs ABATACEPT SUBQ /ML
ABALOPARATIDE vs ABCIXIMAB
ABALOPARATIDE vs ABEMACICLIB
ABALOPARATIDE vs ABILIFY